Biogen’s Alzheimer’s Drug Fails to Meet Mid‑Stage Trial Goal

Biogen has announced that one of its experimental Alzheimer’s drugs failed to meet its main goal in a mid‑stage clinical trial, dealing a setback to the company’s efforts to develop new treatments for the disease. According to Reuters, the drug did not show sufficient effectiveness on the primary measures used to evaluate patient benefit, although researchers will continue to analyse secondary data from the study.
The result underlines the scientific and financial risks involved in Alzheimer’s research, an area where many high‑profile drug candidates have failed in recent years. For Biogen, which has faced intense scrutiny over previous Alzheimer’s treatments, the news adds pressure as investors and regulators look for clear evidence that new therapies can slow or alter the course of the disease.